Literature DB >> 25986726

The nicotinic acetylcholine receptor-mediated reciprocal effects of the tobacco nitrosamine NNK and SLURP-1 on human mammary epithelial cells.

Mina Kalantari-Dehaghi1, Erinn A Parnell2, Tara Armand3, Hans-Ulrich Bernard4, Sergei A Grando5.   

Abstract

Recent research has demonstrated that the nicotinergic signaling network of mammary epithelium can both mediate the physiological control of normal breast epithelial cells (BECs) and exhibit tumor-promoting effects on malignant BECs. Therefore, mammary nicotinic acetylcholine (ACh) receptors (nAChRs) may become a specific target for novel anti-breast cancer therapies. Toward this goal, we investigated the difference in the ACh receptor repertoires between normal and malignant BECs, determined effects of nicotinic ligands on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-dependent activation of ERK1/2 and tumorigenic transformation of MCF10A cells, and characterized reciprocal effects of NNK and SLURP (secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1)-1 on the expression of nAChR subunits and several oncogenes and tumor-suppressing genes in BECs. Both the non-malignant MCF10A and malignant MCF7 breast cells expressed α3, α5, α7, α9, α10, β1, β2, γ, δ and ε nAChR subunits and M(1), M(3), M(4) and M(5) muscarinic receptor subtypes. The malignancy was associated with expression of α1, α4 and β4 nAChR subunits and M(2) subtype. Malignant transformation of BECs was also associated with overexpression of α7-, and α9-made nAChRs. NNK upregulated ERK1/2 phosphorylation, stimulated expression of the gene encoding the tumor-promoter HGF, downregulated expression of the tumor suppressor gene CDKN2A, and induced tumorigenic transformation of MCF10A cells. Compared to the canonical nAChR antagonists, SLURP-1 showed the highest ability to abolish the nAChR-mediated effects of NNK in both cell-signaling and cell-transformation assays and reversed many effects of NNK on gene expression. SLURP-1 also markedly upregulated the tumor suppressor genes CDKN2B, RUNX3 and TP73. Altogether, the obtained results provided new insight into the molecular mechanisms of nAChR-mediated oncogenic effects of NNK on BECs and demonstrated the ability to abolish or reverse these effects by SLURP-1.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gene expression; MCF-10A cells; MCF-7 cells; NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone); Nicotinic acetylcholine receptors, proliferation, breast cancer; SLURP (secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1)-1 and -2

Mesh:

Substances:

Year:  2015        PMID: 25986726     DOI: 10.1016/j.intimp.2015.04.041

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

Review 1.  State of the evidence 2017: an update on the connection between breast cancer and the environment.

Authors:  Janet M Gray; Sharima Rasanayagam; Connie Engel; Jeanne Rizzo
Journal:  Environ Health       Date:  2017-09-02       Impact factor: 5.984

2.  Palmoplantar keratoderma in Slurp1/Slurp2 double-knockout mice.

Authors:  Christopher M Allan; Patrick J Heizer; Cris J Jung; Yiping Tu; Deanna Tran; Lorraine C Young; Loren G Fong; Pieter J de Jong; Anne P Beigneux; Stephen G Young
Journal:  J Dermatol Sci       Date:  2017-09-28       Impact factor: 4.563

3.  Identification of a prognosis‑associated signature associated with energy metabolism in triple‑negative breast cancer.

Authors:  Chao Li; Xujun Li; Guangming Li; Long Sun; Wei Zhang; Jing Jiang; Qidong Ge
Journal:  Oncol Rep       Date:  2020-06-23       Impact factor: 3.906

4.  A System Pharmacology Model for Decoding the Synergistic Mechanisms of Compound Kushen Injection in Treating Breast Cancer.

Authors:  Yi Li; Kexin Wang; Yupeng Chen; Jieqi Cai; Xuemei Qin; Aiping Lu; Daogang Guan; Genggeng Qin; Weiguo Chen
Journal:  Front Pharmacol       Date:  2021-11-16       Impact factor: 5.810

Review 5.  Acetylcholine signaling system in progression of lung cancers.

Authors:  Jamie R Friedman; Stephen D Richbart; Justin C Merritt; Kathleen C Brown; Nicholas A Nolan; Austin T Akers; Jamie K Lau; Zachary R Robateau; Sarah L Miles; Piyali Dasgupta
Journal:  Pharmacol Ther       Date:  2018-10-03       Impact factor: 13.400

6.  Nicotinic acetylcholine receptors and cancer.

Authors:  Ningning Dang; Xianguang Meng; Haiyan Song
Journal:  Biomed Rep       Date:  2016-03-07

7.  Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA.

Authors:  Zhihua Sun; Manqi Zhangsun; Shuai Dong; Yiqiao Liu; Jiang Qian; Dongting Zhangsun; Sulan Luo
Journal:  Mar Drugs       Date:  2020-01-17       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.